bluebird bio Announces Pricing of Public Offering of Common Stock
S&P, Dow rattle cage on uncharted territory
UPDATE: S&P 500, Nasdaq retest major support
UPDATE: Reynolds rises on buyout report; Delta gains altitude
Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...
Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.
Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.